Hormone receptor-positive breast cancer, expanding generic drug access, and emerging applications in prostate cancer are propelling the global Anastrozole market forward.
Industry Overview
Anastrozole This expansion is largely fueled by the growing incidence of hormone receptor-positive breast cancer, mainly among postmenopausal women. Anastrozole, an aromatase inhibitor, is critical in the treatment of this type of cancer by suppressing estrogen levels in the body, thus inhibiting or slowing the development of estrogen-dependent tumors.
The market is also experiencing growth as increased demand for personalized medicines and developments in pharmaceutical technology. Increasing healthcare spending, expansion of healthcare infrastructure, and increasing rates of breast cancer are all going to drive market growth. Further, increasing acceptance and awareness regarding targeted treatments are driving market growth as healthcare professionals more and more prescribe this medication because of its efficacy and favorable side-effect profile.
Click To get a Sample PDF (Including Full TOC, Graphs & Charts, Table & Figures) @
https://api.omrglobal.com/request-sample/Anastrozole-Market/
WHO Response
The objective of the WHO Global Breast Cancer Initiative (GBCI) is to lower global breast cancer mortality by 2.5% annually, thus preventing 2.5 million demises from breast cancer around the world between the years 2020 and 2040. Dropping global breast cancer mortality by 2.5% annually would prevent 25% of breast cancer mortality by the year 2030 and 40% by 2040 in women younger than 70 years. The three pillars towards the realization of these goals are health promotion for early detection, timely diagnosis, and comprehensive breast cancer management. By offering public health education to enhance knowledge among women of breast cancer symptoms and signs and, along with their families, comprehend the significance of early diagnosis and treatment, more women would see medical professionals when breast cancer first arises, and before any cancer may have becomes advanced. This is achievable even without mammographic screening which is not feasible in most nations currently.
For Full Report Description + Research Methodology + Table of Content + Infographics @
https://api.omrglobal.com/report-gallery/anastrozole-market/
Recent Development
- In December 2019, Juvise Pharmaceuticals done the acquisition of AstraZeneca Plc’s commercial rights to Arimidex (Anastrozole) across various countries and increasing their oncology portfolio.
Anastrozole Market Segmentation Analysis
Global Anastrozole Market by Type
- Generic Anastrozole Tablets
- Branded Anastrozole Tablets
Global Anastrozole Market by End users
- Hospitals
- Clinics
- Others
Global Anastrozole Market by Distribution Channels
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- ASEAN Economies (Singapore, Thailand, Vietnam, Indonesia, and Other)
- Australia and New Zealand
- Rest of Asia-Pacific
- Rest of the World
- Latin America
- Middle East and Africa
Anurag Tiwari
Director Sales Division
+91 780-304-0404
info@omrglobal.com
Visit us on social media:
Facebook | X | LinkedIn
